A thromboxane A2 synthetase inhibitor retards hypertensive rat diabetic nephropathy
| Autor: | Satoshi Kunitada, Kiyoshi Irie, Youichi Abe, Hidemi Masumura, Shin-ichiro Ashida |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
medicine.medical_specialty
Tetrahydronaphthalenes Thromboxane Urinary system Prostaglandin Blood Pressure Prostacyclin Kidney Rats Inbred WKY Diabetes Mellitus Experimental Nephropathy Diabetic nephropathy chemistry.chemical_compound Thromboxane A2 Heart Rate Rats Inbred SHR Internal medicine Acetylglucosaminidase medicine Animals Diabetic Nephropathies Pharmacology business.industry Imidazoles gamma-Glutamyltransferase medicine.disease Streptozotocin Rats Thromboxane B2 Proteinuria Endocrinology chemistry Hypertension Prostaglandins Thromboxane-A Synthase business circulatory and respiratory physiology medicine.drug |
| Zdroj: | European Journal of Pharmacology. 210:163-172 |
| ISSN: | 0014-2999 |
| DOI: | 10.1016/0014-2999(92)90667-s |
| Popis: | Spontaneously hypertensive rats (SHR) were injected with streptozotocin (STZ-SHR) to induce diabetes. The effect of DP-1904, a thromboxane A2 synthetase inhibitor, on diabetic nephropathy was then studied by administering it for 5 months (1 or 10 mg/kg). DP-1904 did not affect renal 6-keto prostaglandin (PG)F1 alpha production in STZ-SHR, but markedly inhibited renal thromboxane (TX) B2 production, so that the 6-keto PGF1 alpha/TXB2 ratio was significantly increased (P less than 0.05). STZ-SHR showed significant uraemia and proteinuria, plus increases in urinary gamma-glutamyl-transpeptidase and urinary N-acetyl-beta-glucosaminidase. DP-1904 significantly decreased (P less than 0.01) the urinary changes. STZ-SHR also showed an increase in mesangial periodic acid-Schiff-positive substance and in relative renal weight, both of which were significantly inhibited by DP-1904 (P less than 0.05). Thus, DP-1904 inhibited both TXB2 production and the progression of renal damage in STZ-SHR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|